{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:34:55Z","timestamp":1787805295135,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI161839"],"award-info":[{"award-number":["R01-AI161839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01064-6","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T04:16:18Z","timestamp":1736741778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A broad spectrum Shigella vaccine based on VirG53\u2013353 multiepitope region produced in a cell-free system"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8150-1277","authenticated-orcid":false,"given":"Girmay","family":"Desalegn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8201-995X","authenticated-orcid":false,"given":"Charlotte","family":"Abrahamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ross Turbyfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Pill-Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitradevi S.","family":"Tamilselvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8158-5201","authenticated-orcid":false,"given":"Dylan","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-6452","authenticated-orcid":false,"given":"Neeraj","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheo","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin V.","family":"Oaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-2867","authenticated-orcid":false,"given":"Jeff","family":"Fairman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0894-4009","authenticated-orcid":false,"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","volume":"18","author":"IA Khalil","year":"2018","unstructured":"Khalil, I. A. et al. Morbidity and mortality due to Shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990\u20132016. Lancet Infect. Dis. 18, 1229\u20131240 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1064_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","volume":"392","author":"G DALY","year":"2018","unstructured":"DALY, G. & Collaborators, H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1859 (2018).","journal-title":"Lancet"},{"key":"1064_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/vaccines10091376","volume":"10","author":"CA MacLennan","year":"2022","unstructured":"MacLennan, C. A., Grow, S., Ma, L.-F. & Steele, A. D. The Shigella vaccines pipeline. Vaccines 10, 1376 (2022).","journal-title":"Vaccines"},{"key":"1064_CR4","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.3390\/ijms25084329","volume":"25","author":"T Lu","year":"2024","unstructured":"Lu, T., Das, S., Howlader, D. R., Picking, W. D. & Picking, W. L. Shigella vaccines: the continuing unmet challenge. Int. J. Mol. Sci. 25, 4329 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1064_CR5","unstructured":"Organization, W. H. WHO bacterial priority pathogens list. Geneva: World Health Organization, 12\u201313 (2024)."},{"key":"1064_CR6","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.vaccine.2022.12.037","volume":"41","author":"WP Hausdorff","year":"2023","unstructured":"Hausdorff, W. P. et al. Vaccine value profile for Shigella. Vaccine 41, S76\u2013S94 (2023).","journal-title":"Vaccine"},{"key":"1064_CR7","doi-asserted-by":"publisher","first-page":"21878","DOI":"10.1074\/jbc.271.36.21878","volume":"271","author":"T Suzuki","year":"1996","unstructured":"Suzuki, T., Saga, S. & Sasakawa, C. Functional analysis of Shigella VirG domains essential for interaction with vinculin and actin-based motility. J. Biol. Chem. 271, 21878\u201321885 (1996).","journal-title":"J. Biol. Chem."},{"key":"1064_CR8","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1073\/pnas.92.14.6572","volume":"92","author":"MB Goldberg","year":"1995","unstructured":"Goldberg, M. B. & Theriot, J. A. Shigella flexneri surface protein IcsA is sufficient to direct actin-based motility. Proc. Natl Acad. Sci. 92, 6572\u20136576 (1995).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1064_CR9","doi-asserted-by":"publisher","first-page":"9871","DOI":"10.1073\/pnas.171310498","volume":"98","author":"M Charles","year":"2001","unstructured":"Charles, M., P\u00e9rez, M., Kobil, J. H. & Goldberg, M. B. Polar targeting of Shigella virulence factor IcsA in Enterobacteriacae and Vibrio. Proc. Natl Acad. Sci. 98, 9871\u20139876 (2001).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1064_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.chom.2014.03.001","volume":"15","author":"AB Zumsteg","year":"2014","unstructured":"Zumsteg, A. B., Goosmann, C., Brinkmann, V., Morona, R. & Zychlinsky, A. IcsA is a Shigella flexneri adhesin regulated by the type III secretion system and required for pathogenesis. Cell Host Microbe 15, 435\u2013445 (2014).","journal-title":"Cell Host Microbe"},{"key":"1064_CR11","doi-asserted-by":"publisher","first-page":"e0227425","DOI":"10.1371\/journal.pone.0227425","volume":"15","author":"J Qin","year":"2020","unstructured":"Qin, J., Doyle, M. T., Tran, E. N. H. & Morona, R. The virulence domain of Shigella IcsA contains a subregion with specific host cell adhesion function. PloS One 15, e0227425 (2020).","journal-title":"PloS One"},{"key":"1064_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00797-6","volume":"9","author":"G Desalegn","year":"2024","unstructured":"Desalegn, G. et al. Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate. npj Vaccines 9, 2 (2024).","journal-title":"npj Vaccines"},{"key":"1064_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/bit.23103","volume":"108","author":"JF Zawada","year":"2011","unstructured":"Zawada, J. F. et al. Microscale to manufacturing scale\u2010up of cell\u2010free cytokine production\u2014a new approach for shortening protein production development timelines. Biotechnol. Bioeng. 108, 1570\u20131578 (2011).","journal-title":"Biotechnol. Bioeng."},{"key":"1064_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00253-021-11701-4","volume":"106","author":"N Kapoor","year":"2022","unstructured":"Kapoor, N. et al. Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system. Appl. Microbiol. Biotechnol. 106, 401\u2013414 (2022).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"1064_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/JB.00790-10","volume":"193","author":"K K\u00fchnel","year":"2011","unstructured":"K\u00fchnel, K. & Diezmann, D. Crystal structure of the autochaperone region from the Shigella flexneri autotransporter IcsA. J. Bacteriol. 193, 2042\u20132045 (2011).","journal-title":"J. Bacteriol."},{"key":"1064_CR16","doi-asserted-by":"publisher","first-page":"30874","DOI":"10.1074\/jbc.270.52.30874","volume":"270","author":"T Suzuki","year":"1995","unstructured":"Suzuki, T., Lett, M.-C. & Sasakawa, C. Extracellular transport of VirG protein in Shigella (\u2217). J. Biol. Chem. 270, 30874\u201330880 (1995).","journal-title":"J. Biol. Chem."},{"key":"1064_CR17","doi-asserted-by":"publisher","first-page":"e00412","DOI":"10.1128\/CVI.00412-16","volume":"24","author":"AA Shimanovich","year":"2017","unstructured":"Shimanovich, A. A. et al. Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study. Clin. Vaccin. Immunol. 24, e00412\u2013e00416 (2017).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1064_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111216","volume":"40","author":"B Bernshtein","year":"2022","unstructured":"Bernshtein, B. et al. Systems approach to define humoral correlates of immunity to Shigella. Cell Rep. 40, 111216 (2022).","journal-title":"Cell Rep."},{"key":"1064_CR19","doi-asserted-by":"crossref","unstructured":"Ndungo, E. et al. Repertoire of naturally acquired maternal antibodies transferred to infants for protection against shigellosis. Front. Immunol. 12, 725129 (2021).","DOI":"10.3389\/fimmu.2021.725129"},{"key":"1064_CR20","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1128\/iai.63.10.3927-3935.1995","volume":"63","author":"KR Turbyfill","year":"1995","unstructured":"Turbyfill, K. R., Joseph, S. W. & Oaks, E. V. Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a. Infect. Immun. 63, 3927\u20133935 (1995).","journal-title":"Infect. Immun."},{"key":"1064_CR21","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1128\/IAI.66.5.1999-2006.1998","volume":"66","author":"KR Turbyfill","year":"1998","unstructured":"Turbyfill, K. R., Mertz, J. A., Mallett, C. P. & Oaks, E. V. Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD). Infect. Immun. 66, 1999\u20132006 (1998).","journal-title":"Infect. Immun."},{"key":"1064_CR22","doi-asserted-by":"crossref","unstructured":"Suzuki, T., Miki, H., Takenawa, T. & Sasakawa, C. Neural Wiskott\u2013Aldrich syndrome protein is implicated in the actin\u2010based motility of Shigella flexneri. EMBO J. 17, 2767\u20132776 (1998).","DOI":"10.1093\/emboj\/17.10.2767"},{"key":"1064_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1128\/jb.171.1.353-359.1989","volume":"171","author":"M Lett","year":"1989","unstructured":"Lett, M. et al. virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the virG protein and determination of the complete coding sequence. J. Bacteriol. 171, 353\u2013359 (1989).","journal-title":"J. Bacteriol."},{"key":"1064_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.1601775","volume":"199","author":"PN Boyaka","year":"2017","unstructured":"Boyaka, P. N. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9\u201316 (2017).","journal-title":"J. Immunol."},{"key":"1064_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","volume":"30","author":"SG Reed","year":"2009","unstructured":"Reed, S. G., Bertholet, S., Coler, R. N. & Friede, M. New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23\u201332 (2009).","journal-title":"Trends Immunol."},{"key":"1064_CR26","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.3390\/ijms21176144","volume":"21","author":"FR Shepherd","year":"2020","unstructured":"Shepherd, F. R. & McLaren, J. E. T cell immunity to bacterial pathogens: mechanisms of immune control and bacterial evasion. Int. J. Mol. Sci. 21, 6144 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1064_CR27","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.4049\/jimmunol.163.12.6448","volume":"163","author":"JM Brewer","year":"1999","unstructured":"Brewer, J. M. et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J. Immunol. 163, 6448\u20136454 (1999).","journal-title":"J. Immunol."},{"key":"1064_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043109","volume":"14","author":"SK Verma","year":"2023","unstructured":"Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109 (2023).","journal-title":"Front. Immunol."},{"key":"1064_CR29","doi-asserted-by":"crossref","unstructured":"Li, S. et al. A broadly immunogenic polyvalent Shigella multiepitope fusion antigen protein protects against Shigella sonnei and Shigella flexneri lethal pulmonary challenges in mice. Infect. Immun. 91, e0031623 (2023).","DOI":"10.1128\/iai.00316-23"},{"key":"1064_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.molimm.2019.09.018","volume":"116","author":"M Nosrati","year":"2019","unstructured":"Nosrati, M. et al. Designing a multi-epitope vaccine for cross-protection against Shigella spp: an immunoinformatics and structural vaccinology study. Mol. Immunol. 116, 106\u2013116 (2019).","journal-title":"Mol. Immunol."},{"key":"1064_CR31","doi-asserted-by":"publisher","first-page":"108132","DOI":"10.1016\/j.intimp.2021.108132","volume":"100","author":"A Felegary","year":"2021","unstructured":"Felegary, A., Nazarian, S., Kordbacheh, E., Fathi, J. & Minae, M. E. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella. Int. Immunopharmacol. 100, 108132 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"1064_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.molimm.2024.07.002","volume":"173","author":"A Felegary","year":"2024","unstructured":"Felegary, A. et al. Evaluation of the prophylactic effect of egg yolk antibody (IgY) produced against the recombinant protein containing IpaD, IpaB, StxB, and VirG proteins from Shigella. Mol. Immunol. 173, 53\u201360 (2024).","journal-title":"Mol. Immunol."},{"key":"1064_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","volume":"349","author":"D Cohen","year":"1997","unstructured":"Cohen, D. et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349, 155\u2013159 (1997).","journal-title":"Lancet"},{"key":"1064_CR34","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","volume":"28","author":"JH Passwell","year":"2010","unstructured":"Passwell, J. H. et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134-year-old Israeli children. Vaccine 28, 2231\u20132235 (2010).","journal-title":"Vaccine"},{"key":"1064_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103310","volume":"66","author":"KR Talaat","year":"2021","unstructured":"Talaat, K. R. et al. Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection. EBioMedicine 66, 103310 (2021).","journal-title":"EBioMedicine"},{"key":"1064_CR36","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","volume":"21","author":"D Cohen","year":"2021","unstructured":"Cohen, D. et al. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. Lancet Infect. Dis. 21, 546\u2013558 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1064_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/vaccines10010033","volume":"10","author":"Y Mo","year":"2022","unstructured":"Mo, Y. et al. Safety and immunogenicity of a Shigella bivalent conjugate vaccine (ZF0901) in 3-month-to 5-year-old children in China. Vaccines 10, 33 (2022).","journal-title":"Vaccines"},{"key":"1064_CR38","unstructured":"WHO. WHO preferred product characteristics for vaccines against Shigella. World Health Organization: Geneva, Switzerland. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/349841\/9789240036741-eng.pdf (2021)."},{"key":"1064_CR39","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/IAI.06174-11","volume":"80","author":"FJ Martinez-Becerra","year":"2012","unstructured":"Martinez-Becerra, F. J. et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect. Immun. 80, 1222\u20131231 (2012).","journal-title":"Infect. Immun."},{"key":"1064_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/infdis\/164.3.533","volume":"164","author":"SB Formal","year":"1991","unstructured":"Formal, S. B. et al. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J. Infect. Dis. 164, 533\u2013537 (1991).","journal-title":"J. Infect. Dis."},{"key":"1064_CR41","doi-asserted-by":"publisher","first-page":"e00019","DOI":"10.1128\/msphere.00019-23","volume":"8","author":"G Desalegn","year":"2023","unstructured":"Desalegn, G. et al. A novel Shigella O-polysaccharide\u2013IpaB Conjugate vaccine elicits robust antibody responses and confers protection against multiple Shigella serotypes. Msphere 8, e00019\u2013e00023 (2023).","journal-title":"Msphere"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01064-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01064-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01064-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:06:51Z","timestamp":1736784411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01064-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01064-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F., N.K., C.A., L.P.P., L.B., B.S., and M.H. are employees of Vaxcyte, Inc. The remaining authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}